Atsushi Horiike

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Journal: Frontiers in immunology

Published: March 10, 2026

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Journal: Scientific reports

Published: February 05, 2026

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: February 05, 2026

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 26, 2025

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 31, 2025

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Journal: Biomedicines

Published: October 30, 2025

Increased alanine aminotransferase level as a predictive marker of hand-foot syndrome in patients receiving capecitabine: A retrospective cohort study.

Increased alanine aminotransferase level as a predictive marker of hand-foot syndrome in patients receiving capecitabine: A retrospective cohort study.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: October 24, 2025

Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.

Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.

Journal: Journal of hepato-biliary-pancreatic sciences

Published: October 21, 2025

Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors - Summary of recommendations.

Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors - Summary of recommendations.

Journal: Respiratory investigation

Published: August 09, 2025

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Journal: Cancers

Published: June 12, 2025

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Journal: Frontiers in immunology

Published: June 03, 2025

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Journal: Frontiers in oncology

Published: April 18, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026